Our Abpromise guarantee covers the use of ab33917 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500. Detects a band of approximately 70 kDa (predicted molecular weight: 62 kDa).
IHC-P 1/100 - 1/250.
IP 1/50.
ICC/IF 1/250 - 1/500.
  • Application notesIs unsuitable for Flow Cyt.
  • Target

    • FunctionNF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49.
    • Sequence similaritiesContains 1 RHD (Rel-like) domain.
    • DomainBoth N- and C-terminal domains are required for transcriptional activation.
    • Post-translational
      Phosphorylation at 'Thr-103' and 'Ser-573' is followed by proteasomal degradation.
    • Cellular localizationNucleus. Cytoplasm > cytoskeleton > centrosome. Co-localizes with NEK6 in the centrosome.
    • Information by UniProt
    • Database links
    • Alternative names
      • I REL antibody
      • I-Rel antibody
      • IREL antibody
      • Nuclear factor of kappa light polypeptide gene enhancer in B cells 3 antibody
      • relB antibody
      • RELB_HUMAN antibody
      • Reticuloendotheliosis viral oncogene homolog B antibody
      • Transcription factor Rel B antibody
      • Transcription factor RelB antibody
      • v rel avian reticuloendotheliosis viral oncogene homolog B antibody
      • v rel reticuloendotheliosis viral oncogene homolog B antibody
      see all

    Anti-Rel B antibody [EP613Y] images

    • All lanes : Anti-Rel B antibody [EP613Y] (ab33917) at 1/500 dilution

      Lane 1 : 10ug Raji cell lysate
      Lane 2 : 10ug Daudi cell lysate

      Goat anti-rabbit HRP labeled.

      Predicted band size : 62 kDa
    • Immunohistochemical analysis of paraffin-embedded human lymphoma using ab33917

    References for Anti-Rel B antibody [EP613Y] (ab33917)

    This product has been referenced in:
    • Siak JJ  et al. The nuclear-factor kappaB pathway is activated in pterygium. Invest Ophthalmol Vis Sci 52:230-6 (2011). Read more (PubMed: 20811049) »
    • Huang Y  et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood 115:1226-37 (2010). Read more (PubMed: 19965620) »

    See all 2 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab33917.
    Please use the links above to contact us or submit feedback about this product.